Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633839 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults
A Phase 1 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02633839 is a Phase 1 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT02633839, a Phase 1 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an open label, parallel group study to evaluate the pharmacokinetics (PK) and safety of a single dose of CVT-301 in smoking and non-smoking adults.
Interventions
- DRUG Carbidopa
- DRUG CVT-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02633839
The ClinicalTrials.gov registry entry for NCT02633839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carbidopa is the first listed.
NCT02633839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02633839 about?
NCT02633839 is a clinical study titled "A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults". This is an open label, parallel group study to evaluate the pharmacokinetics (PK) and safety of a single dose of CVT-301 in smoking and non-smoking adults.
What is the current status of trial NCT02633839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-12. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02633839?
The interventions under investigation include: Carbidopa (DRUG), CVT-301 (DRUG).
Who is sponsoring clinical trial NCT02633839?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.